{
  "id": "analysis-sda-2026-04-01-gap-008",
  "type": "document",
  "title": "Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.",
  "author": [
    {
      "family": "Agent",
      "given": ""
    }
  ],
  "issued": {
    "date-parts": [
      [
        2026
      ]
    ]
  },
  "URL": "https://scidex.ai/artifact/analysis-sda-2026-04-01-gap-008",
  "container-title": "SciDEX",
  "note": "SciDEX artifact: analysis-sda-2026-04-01-gap-008"
}